Japanese researchers have developed a new rat model of thromboembolic ischemic stroke that did not require arterial ligation of the external carotid artery, which makes the research for thrombolytic agents more complicated.
Trawsfynydd Therapeutics Inc. has received approval to initiate a first-in-man phase I trial of the novel best-in-class COVID-19 treatment, TRX-01, an inhibitor targeting the SARS-CoV-2 viral main protease (3CL, Mpro).
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration and option agreement with Shattuck Labs Inc. to generate bifunctional fusion proteins.
It is known that CX3C chemokine receptor 1 (CX3CR1) expressed on macrophages plays a crucial role in inner hair cell ribbon synaptic repair and spiral ganglion neuron survival after synaptopathic noise-induced trauma.
Valirx plc has signed an over-arching agreement with the University of Dundee and its drug discovery unit (DDU) to access research relating to novel therapeutic candidates.
Medigene AG has selected initial clinical indications for its lead candidate, MDG-1015, specifically gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.
Researchers from Broad Institute Inc. and affiliated organizations have reported data from a study that highlighted a new variant-to-gene-to-program (V2G2P) approach designed to link variants from genome-wide association studies (GWAS) to genes and identify their convergence onto specific disease-associated transcriptional programs.
Les Laboratories Servier SAS and Vernalis (R&D) Ltd. have described induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors acting as apoptosis inducers reported to be useful for the treatment of cancer and autoimmune diseases.
Aurigene Oncology Ltd. has divulged cyclin-dependent kinase 12 (CDK12) and/or cyclin-dependent kinase 13 (CDK13) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, infections, amyotrophic lateral sclerosis, frontotemporal dementia, spinal and bulbar muscular atrophy, spinocerebellar ataxia and Huntington’s disease, among others.
RSS
